On the daily chart of Hims & Hers Health, we’re looking at a textbook cup with handle formation — not just a pattern, but a structure backed by time, volume, and classic price behavior. The base of the cup formed steadily from February to May 2025, and as soon as the curve was complete, price transitioned into a tight consolidation — the "handle" that often masks real accumulation.
Right now, price is testing the resistance area. And it’s not just floating up there — it’s coming in hot: price has already broken through EMA 20/50/100/200 and SMA 50/200. That’s a full stack flip. This isn’t sideways noise — it’s a structural shift in control.
Volume is starting to build as price rises, confirming that demand is real and institutional positioning likely active. We’re watching a breakout zone above the handle — and when that breaks, the structure unlocks with a clear target: $107.25, roughly a 2x move from current levels.
This setup isn’t noise. It’s a long-cooked formation that’s now about to boil over. If the handle holds and price breaks through — the rest is just follow-through.
Right now, price is testing the resistance area. And it’s not just floating up there — it’s coming in hot: price has already broken through EMA 20/50/100/200 and SMA 50/200. That’s a full stack flip. This isn’t sideways noise — it’s a structural shift in control.
Volume is starting to build as price rises, confirming that demand is real and institutional positioning likely active. We’re watching a breakout zone above the handle — and when that breaks, the structure unlocks with a clear target: $107.25, roughly a 2x move from current levels.
This setup isn’t noise. It’s a long-cooked formation that’s now about to boil over. If the handle holds and price breaks through — the rest is just follow-through.
Trade active
Hims & Hers loses Novo Nordisk partnership — and with it, market confidencePharma giant Novo Nordisk has terminated its partnership with the telehealth platform Hims & Hers, cutting off direct access to the FDA-approved weight loss drug Wegovy via its NovoCare pharmacy network.
Novo accused Hims of violating laws on compounded medications and spreading misleading marketing that could compromise patient safety. The company also raised concerns about unauthorized ingredient sourcing, including raw materials from China.
Hims & Hers denies wrongdoing and claims Novo applied anti-competitive pressure to steer patients exclusively toward Wegovy, stating the drug remains available on its platform.
For the market, this is a textbook case of reputational and structural risk:
HIMS shares dropped sharply as investors priced in regulatory exposure and brand damage.
Novo is clearly protecting Wegovy, a critical growth engine within its GLP-1 portfolio.
This move likely signals increased scrutiny on telemedicine models and compounding practices in weight loss therapeutics.
When a company’s business model depends on access to a branded product without full supply chain control, it becomes vulnerable. We’re now seeing this play out in real time.
More to come as the story develops.
👨🎓 Наш телеграм t.me/totoshkatrading
🉐 Платформы linktr.ee/totoshka55
💬 Наши контакты @Totoshkatips
🔗 Сайт totoshkatrades.com
🉐 Платформы linktr.ee/totoshka55
💬 Наши контакты @Totoshkatips
🔗 Сайт totoshkatrades.com
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
👨🎓 Наш телеграм t.me/totoshkatrading
🉐 Платформы linktr.ee/totoshka55
💬 Наши контакты @Totoshkatips
🔗 Сайт totoshkatrades.com
🉐 Платформы linktr.ee/totoshka55
💬 Наши контакты @Totoshkatips
🔗 Сайт totoshkatrades.com
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.